SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-012310
Filing Date
2020-05-07
Accepted
2020-05-07 19:39:41
Documents
2
Period of Report
2020-05-07

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1602
2 EX-24 DOCUMENT attachment1.htm EX-24 4109
  Complete submission text file 0000899243-20-012310.txt   7126
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Issuer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O AYALA PHARMACEUTICALS, INC. OPPENHEIMER 4 REHOVOT L3 7670104
Business Address
Sone Todd (Reporting) CIK: 0001811299 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39279 | Film No.: 20858250